Objectives-To clarify the pathophysiological role of endothelin-1 (ET-1) in the vascular injury associated with systemic lupus erythematosus (SLE) by investigating the effect of sera from patients with SLE on ET-1 release from cultured human umbilical vein endothelial cells. Methods-Confluent monolayers of cultured human umbilical vein endothelial cells were incubated with serum samples (diluted 1:10) from 25 patients with SLE and 16 normal controls for two hours at 37°C and ET-1 concentration in the culture supernatant was measured by enzyme iunmunoassay.
Results-The mean release of ET-1 from endothelial cells in the presence of serum from SLE patients was greater than in the presence of serum from normal controls (p < 0-005). ET-1 release from endothelial cells significantly correlated with the titre of IgM anti-endothelial cell antibodies (IgM-AECA) and immune complex concentration in sera from SLE patients (p < 0 05 and p < 0*01, respectively). After gel chromatography of the serum from an SLE patient, those fractions containing IgM-AECA or immune complex were shown to stimulate ET-1 release from endothelial cells. Heat aggregated IgG also stimulated ET-1 release from endothelial cells in a concentration dependent manner. Conclusions-IgM-AECA and immune complexes may stimulate ET-1 release from endothelial cells and ET-1 may play an important role in the initiation and development of vascular injury, such as pulmonary hypertension and lupus nephritis, in SLE.
(Ann Rheum Dis 1995; 54: 361-365)
Endothelin-1 (ET-1), a 21 amino acid polypeptide with two intramolecular disulphide bonds, is produced by endothelial cells and induces sustained vasoconstriction in vitro and a long lasting increase in blood pressure in vivo.' In addition, ET-1 stimulates the proliferation and contraction of vascular smooth muscle cells and mesangial cells.Y6 Such actions may have an important pathophysiological role in the initiation and development of vascular injury such as lupus nephritis and pulmonary hypertension in patients with systemic lupus erythematosus (SLE). Indeed, high plasma concentrations of ET-1 have been demonstrated in patients with SLE and were shown to be significantly correlated with a history of nephritis.7 A significant increase in plasma ET-1 concentration has also been observed in patients with Raynaud's phenomenon, including patients with SLE, immediately after immersion of their hands in cold water.8 Moreover, the concentration of ET-1 in arterial plasma is greater than that in venous plasma in patients with primary pulmonary hypertension, and it has been suggested that pulmonary production of ET- Test samples were prepared in three different volumes for use in separate studies: 250 ,l samples of serum fractions; 500 pAl samples of whole serum diluted 1:10 in PBS; and 1 ml samples of monomeric or heat aggregated IgG diluted serially in PBS. The samples were added to each well, and the cells incubated for two hours at 37°C. The supernatant in each well was then collected and stored at -20°C until required for assay of ET-1. After removal of the supematant, the cell monolayer remained confluent. All samples were tested in triplicate, and the results were averaged.
The concentration of ET-1 was measured in cell supematants by the enzyme immunoassay developed by Suzuki et al. '3 The assay, which uses two different antibodies for capture and detection of ET-1, has a lower limit of detection of 0G4 pg/ml of ET-1, and does not cross react with big ET-1 or ET-3.
FRACTIONATION OF SERA
Serum from one normal control that did not significantly stimulate ET-1 release from endothelial cells and serum from one SLE patient that did significantly stimulate ET-1 release from endothelial cells were fractionated in an attempt to identify the components responsible for stimulation of ET-1 release. The serum samples (1 ml) were applied to a Sephacryl S-200 (Pharmacia, Woerden, The Netherlands) column (1-5 X 120 cm) that had been equilibrated in 0 01 molI PBS (pH 7 2). The fractions (2 ml 
Results

EFFECT ON ET-1 RELEASE OF PBS ALONE
The endothelial cell preparation used in the evaluation of the effects of monomeric and heat aggregated IgG on ET-1 was found to release 20-0 pg/1-5 X 105 cells when incubated in the presence of PBS alone. The two used in the evaluation of both whole and fractionated sera from SLE patients and normal controls each released 34 0 pg/1-5 x 105 cells in the presence of PBS alone.
EFFECT OF SERUM FROM NORMAL CONTROLS AND SLE PATIENTS
ET-1 release from endothelial cells in the presence of serum from SLE patients (88-6 (17-9) pg/1-5 x105 cells) was significantly greater (p<0 0A005) than that in the presence of serum from normal controls (72-6 (7 2) pg/1-5 X 105 cells) (fig 1) . The release of ET-1 in the presence of serum from 15 of the 25 patients with SLE was greater than the mean +2SD for normal controls (86-9 pg/1-5 X 105 cells).
Endothelin 
EFFECT OF FRACTIONS OF NORMAL CONTROL AND SLE PATIENT SERUM ON ET-1 RELEASE
The elution profile of IgM-AECA for the normal serum sample showed a peak titre of 0 3 U/ml, which corresponded to the peak of IgM (fig 4) . 
